.... and what's more, the following suggests that if the science...

.... and what's more, the following suggests that if the science works in humans as it did in the animal models, our CAR-T-CDH17 therapy could get the monopoly on the Colorectal, various NET and a sizeable chunk of the Gastric Cancer markets. With the percentage of NET tumours expressing CDH17 protein being 100%, and the presence of the same protein in healthy tissue being hidden from detection, essentially means that our therapy has up to a potential 100% target rate within this area of unmet need. It also suggests to me, the diagnostic process is simplified (no need for a repertoire of biomarkers to determine a NET patient's suitability for our treatment). Its going to come down to how well it does its job in destroying 100% of the vulnerable NET tumours, 98% of Colorectal and 48% of Gastric Tumours.... ie. its efficacy rate. Bring on the data, please!